Cargando…
Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization
We review aspects of the antibody response to SARS-CoV-2, the causative agent of the COVID-19 pandemic. The topics we cover are relevant to immunotherapy with plasma from recovered patients, monoclonal antibodies against the viral S-protein, and soluble forms of the receptor for the virus, angiotens...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311167/ https://www.ncbi.nlm.nih.gov/pubmed/32573433 http://dx.doi.org/10.7554/eLife.57877 |
_version_ | 1783549498919747584 |
---|---|
author | Klasse, PJ Moore, John P |
author_facet | Klasse, PJ Moore, John P |
author_sort | Klasse, PJ |
collection | PubMed |
description | We review aspects of the antibody response to SARS-CoV-2, the causative agent of the COVID-19 pandemic. The topics we cover are relevant to immunotherapy with plasma from recovered patients, monoclonal antibodies against the viral S-protein, and soluble forms of the receptor for the virus, angiotensin converting enzyme 2. The development of vaccines against SARS-CoV-2, an essential public health tool, will also be informed by an understanding of the antibody response in infected patients. Although virus-neutralizing antibodies are likely to protect, antibodies could potentially trigger immunopathogenic events in SARS-CoV-2-infected patients or enhance infection. An awareness of these possibilities may benefit clinicians and the developers of antibody-based therapies and vaccines. |
format | Online Article Text |
id | pubmed-7311167 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | eLife Sciences Publications, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-73111672020-06-24 Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization Klasse, PJ Moore, John P eLife Microbiology and Infectious Disease We review aspects of the antibody response to SARS-CoV-2, the causative agent of the COVID-19 pandemic. The topics we cover are relevant to immunotherapy with plasma from recovered patients, monoclonal antibodies against the viral S-protein, and soluble forms of the receptor for the virus, angiotensin converting enzyme 2. The development of vaccines against SARS-CoV-2, an essential public health tool, will also be informed by an understanding of the antibody response in infected patients. Although virus-neutralizing antibodies are likely to protect, antibodies could potentially trigger immunopathogenic events in SARS-CoV-2-infected patients or enhance infection. An awareness of these possibilities may benefit clinicians and the developers of antibody-based therapies and vaccines. eLife Sciences Publications, Ltd 2020-06-23 /pmc/articles/PMC7311167/ /pubmed/32573433 http://dx.doi.org/10.7554/eLife.57877 Text en © 2020, Klasse and Moore http://creativecommons.org/licenses/by/4.0/ http://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Microbiology and Infectious Disease Klasse, PJ Moore, John P Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization |
title | Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization |
title_full | Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization |
title_fullStr | Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization |
title_full_unstemmed | Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization |
title_short | Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization |
title_sort | antibodies to sars-cov-2 and their potential for therapeutic passive immunization |
topic | Microbiology and Infectious Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311167/ https://www.ncbi.nlm.nih.gov/pubmed/32573433 http://dx.doi.org/10.7554/eLife.57877 |
work_keys_str_mv | AT klassepj antibodiestosarscov2andtheirpotentialfortherapeuticpassiveimmunization AT moorejohnp antibodiestosarscov2andtheirpotentialfortherapeuticpassiveimmunization |